Risk Stratification and Adjuvant Chemotherapy for High‐Risk Stage IA Lung Adenocarcinoma: The Unmet Needs
Thoracic Cancer · 2025
DOI: 10.1111/1759-7714.15521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Chen Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Shenkang Hospital Development Center, Shanghai Municipal Hospital Development Center.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
To identify high‐risk patients for recurrence in resected stage IA lung adenocarcinoma and evaluate the impact of adjuvant chemotherapy (ACT) on their prognosis, as well as explore potential novel adjuvant therapies.
Methods
Consecutive stage IA patients with ≥ 5% solid or micropapillary subtypes were analyzed. A nomogram was developed using Cox proportional hazards regression to predict recurrence‐free survival (RFS). In the high‐risk group after stratification, RFS was compared between patients receiving ACT and those under observation, as well as between patients with and without driver gene alterations.
Results
This real‐world study included 1328 patients, with a 5‐year RFS of 79.0%. T stage and predominant subtype were independent risk factors for RFS. Patients with T1c or solid/micropapillary‐predominant tumors were stratified into a high‐risk group ( n = 483) using the nomogram. A significant difference in 5‐year RFS was observed between the high‐ and low‐risk groups (73.6% vs. 84.3%, p < 0.001). Among high‐risk patients, sixty‐seven (13.8%) received ACT; however, there was no improvement in 5‐year RFS compared to observation alone (69.1% vs. 75.0%, p = 0.655). Testing rates for EGFR mutation and ALK fusion among high‐risk patients were only 52.4% and 43.9%, respectively, while mutation rates reached up to 55.7% and 9.4%, respectively. These molecular alterations exhibited numerically worse 5‐year RFS compared to wild‐type (EGFR mutation, 70.6% vs. 87.8%, p = 0.108; ALK fusion, 66.3% vs. 73.6%, p = 0.404), though not significant.
Conclusions
ACT failed to meet the needs of stage IA patients with histological high‐risk features. Further exploration of effective adjuvant target therapies is warranted for this patient subgroup.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Chen Shen
Förderung
- Shanghai Shenkang Hospital Development Center
- Shanghai Municipal Hospital Development Center
Zitieren
APA
Shen, C., Liu, H., Li, B., Wang, J., Wang, Y., Bao, F., Gu, Z., & Fang, W. (2025). Risk Stratification and Adjuvant Chemotherapy for High‐Risk Stage IA Lung Adenocarcinoma: The Unmet Needs. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15521
Vancouver
Shen C, Liu H, Li B, Wang J, Wang Y, Bao F, et al. Risk Stratification and Adjuvant Chemotherapy for High‐Risk Stage IA Lung Adenocarcinoma: The Unmet Needs. Thoracic Cancer. 2025. doi:10.1111/1759-7714.15521
BibTeX
@article{Shen2025,
author = {Shen, Chen and Liu, Haoran and Li, Bofei and Wang, Jiaming and Wang, Yiyang and Bao, Feichao and Gu, Zhitao and Fang, Wentao},
title = {Risk Stratification and Adjuvant Chemotherapy for High‐Risk Stage IA Lung Adenocarcinoma: The Unmet Needs},
journal = {Thoracic Cancer},
year = {2025},
doi = {10.1111/1759-7714.15521}
}
EUVIMED